Similar to other therapies, approximately 40% of patients with vitiligo who stopped treatment with ruxolitinib cream relapsed, but they achieved repigmentation once treatment was reinitiated, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
This content was produced independently by The American Journal of Managed Care® and is not endorsed by the American Academy of Dermatology.
Similar to other therapies, approximately 40% of patients with vitiligo who stopped treatment with ruxolitinib cream relapsed, but they achieved repigmentation once treatment was reinitiated, explained John Harris, MD, PhD, FAAD, director of the Vitiligo Clinic and Research Center at UMass Chan Medical School.
At the annual meeting of the American Aca b Dermatology, Harris presented results from the withdrawal arm of the TRuE-V extension study.
Transcript
How long were patients with vitiligo on ruxolitinib cream in the randomized withdrawal arm of the TRuE-V extension study, and what did you find regarding relapse once they were taken off treatment?
We know from published reports that relapse to other typical conventional therapies is about 40% within a year of stopping any treatment for vitiligo. One of the big questions was this new topical JAK [Janus kinase] inhibitor, ruxolitinib, how would it behave and what we would we see in patients? We saw that patients do relapse after stopping the treatment. It appears that the JAK inhibitor doesn't create long-term, durable responses, but it's not any worse, certainly.
When we say 40% of patients relapse within a year, that means 60% don't relapse within a year, and 60% get long-term benefit. We see that with the topical ruxolitinib, as well. Part of that study was to stop patients who had achieved a certain amount of repigmentation—more than 90%, repigmentation—and then either continue to treat them with drug or treat them with placebo and then see how that changes. Then, those who relapsed, put them back on the drug and see how they do.
It was interesting, we certainly saw some relapse—like I said, it was not worse than what we've seen before. When we put them back on drug, they achieved repigmentation again, so there was no tachyphylaxis or lack of response to reinitiation of drug. In some patients, too, we also saw those who continued on drug also could experience some relapse. But the good news is, as they continued on the drug, those that relapsed actually repigmented again.
It appears that there's some dynamic changes that occur, even when drug is continued. That can be seasonal changes. We know that the drug does a little bit better when getting some light. Maybe during summer, they went over the VASI [Vitiligo Area Scoring Index] 90, and then in the winter kind of pulled back a little bit and vacillated. That's one possibility.
But overall, the take-home message is that relapse does occur, but we're able to get great responses again after re-exposure to the drug.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More